Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 5Phase 1 5Phase EARLY_PHASE1 3Phase 3 1

Status

Completed 31Recruiting 27Terminated 26Active not recruiting 13Withdrawn 5Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Select Advanced Solid Tumors 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × atezolizumab × Clear all
NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Immunocore Ltd

Phase 1/2 Withdrawn
Other solid neoplasm

Select Advanced Solid Tumors

NCT06006286 2024-08-26

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

Phase 1/2 Withdrawn
DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT05109052 2023-07-13

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

University of Rochester

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03973879 2020-02-11

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Duke University

Phase 1/2 Withdrawn
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡